soul trial oral semaglutide cardiovascular outcomes results 2025 nejm Cuts Risk by 14% in The SOUL Study - by

SOME 82 Brits have died after using weight-loss and diabetes jabs such as Ozempic and Mounjaro.Sounds pretty scary, doesn't it

NCT02692716.

Developed by Novo Nordisk, Ozempic aids in glycemic control and offers the dual benefit of potential weight loss for individuals managing this chronic condition

Schedule your free consultation.

Clear expectations around recovery, potential complications and long term adjustments can help people feel more prepared and supported throughout their care journey.

Results Once-a-month single-dose semaglutide microcapsule was developed, which effectively suppressed the initial burst release down to 10%, maintained therapeutic plasma drug concentration for a month, and improved the surface appearance of microcapsules